Corbus Accounts Payable vs Cash Analysis

CRBP Stock

USD 16.73 0.65 4.04%

Corbus Pharmaceuticals financial indicator trend analysis is way more than just evaluating Corbus Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corbus Pharmaceuticals is a good investment. Please check the relationship between Corbus Pharmaceuticals Accounts Payable and its Cash accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

Accounts Payable vs Cash

Accounts Payable vs Cash Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corbus Pharmaceuticals Accounts Payable account and Cash. At this time, the significance of the direction appears to have strong relationship.

The correlation between Corbus Pharmaceuticals' Accounts Payable and Cash is 0.65. Overlapping area represents the amount of variation of Accounts Payable that can explain the historical movement of Cash in the same time period over historical financial statements of Corbus Pharmaceuticals Holding, assuming nothing else is changed. The correlation between historical values of Corbus Pharmaceuticals' Accounts Payable and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Accounts Payable of Corbus Pharmaceuticals Holding are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Accounts Payable i.e., Corbus Pharmaceuticals' Accounts Payable and Cash go up and down completely randomly.

Correlation Coefficient

0.65

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Accounts Payable

An accounting item on the balance sheet that represents Corbus Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Corbus Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Cash

Cash refers to the most liquid asset of Corbus Pharmaceuticals, which is listed under current asset account on Corbus Pharmaceuticals Holding balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Corbus Pharmaceuticals customers. The amounts must be unrestricted with restricted cash listed in a different Corbus Pharmaceuticals account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.

Most indicators from Corbus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corbus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corbus Pharmaceuticals Holding. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

As of 11/22/2024, Sales General And Administrative To Revenue is likely to grow to 21.89, while Selling General Administrative is likely to drop slightly above 13.9 M.

Corbus Pharmaceuticals fundamental ratios Correlations

	Common Stock Shares Outstanding	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other
Common Stock Shares Outstanding		-0.17	0.11	-0.19	-0.16	-0.19	-0.18	0.41	-0.04	-0.34	-0.34	-0.04	-0.16	-0.17	0.08	-0.27	0.03	-0.07	-0.18	0.09	-0.3	-0.31	-0.07	-0.1	-0.08	0.03
Total Assets	-0.17		0.77	0.71	0.64	0.84	0.59	-0.44	-0.69	0.52	0.76	0.69	0.98	0.77	0.82	0.66	0.8	0.82	1.0	0.23	0.76	0.18	0.87	0.78	0.79	0.21
Short Long Term Debt Total	0.11	0.77		0.64	0.67	0.47	0.47	0.06	-0.88	0.31	0.39	0.75	0.73	0.82	0.89	0.46	0.95	0.88	0.75	0.5	0.41	-0.31	0.67	0.77	0.8	0.46
Other Current Liab	-0.19	0.71	0.64		0.95	0.34	0.85	-0.43	-0.63	0.91	0.69	0.82	0.62	0.68	0.6	0.94	0.67	0.93	0.67	0.29	0.59	0.04	0.43	0.95	0.94	0.36
Total Current Liabilities	-0.16	0.64	0.67	0.95		0.23	0.7	-0.3	-0.74	0.85	0.59	0.86	0.54	0.77	0.51	0.9	0.76	0.92	0.6	0.48	0.46	0.03	0.45	0.88	0.89	0.54
Total Stockholder Equity	-0.19	0.84	0.47	0.34	0.23		0.37	-0.55	-0.27	0.2	0.7	0.25	0.92	0.38	0.65	0.35	0.49	0.44	0.86	-0.2	0.79	0.39	0.81	0.41	0.41	-0.26
Current Deferred Revenue	-0.18	0.59	0.47	0.85	0.7	0.37		-0.47	-0.27	0.76	0.63	0.47	0.54	0.32	0.61	0.8	0.37	0.74	0.55	-0.12	0.72	-0.15	0.22	0.84	0.82	-0.05
Net Debt	0.41	-0.44	0.06	-0.43	-0.3	-0.55	-0.47		-0.14	-0.54	-0.89	-0.06	-0.48	-0.07	-0.13	-0.5	-0.01	-0.24	-0.45	0.37	-0.56	-0.64	-0.34	-0.24	-0.23	0.23
Retained Earnings	-0.04	-0.69	-0.88	-0.63	-0.74	-0.27	-0.27	-0.14		-0.39	-0.3	-0.88	-0.59	-0.96	-0.64	-0.52	-0.94	-0.82	-0.67	-0.8	-0.2	0.16	-0.65	-0.72	-0.75	-0.76
Accounts Payable	-0.34	0.52	0.31	0.91	0.85	0.2	0.76	-0.54	-0.39		0.65	0.68	0.42	0.5	0.32	0.93	0.4	0.72	0.48	0.12	0.48	0.25	0.19	0.8	0.78	0.22
Cash	-0.34	0.76	0.39	0.69	0.59	0.7	0.63	-0.89	-0.3	0.65		0.42	0.76	0.47	0.51	0.68	0.44	0.63	0.77	-0.06	0.69	0.46	0.62	0.58	0.58	0.05
Long Term Debt	-0.04	0.69	0.75	0.82	0.86	0.25	0.47	-0.06	-0.88	0.68	0.42		0.57	0.86	0.59	0.71	0.84	0.88	0.65	0.61	0.33	0.07	0.51	0.83	0.84	0.61
Cash And Short Term Investments	-0.16	0.98	0.73	0.62	0.54	0.92	0.54	-0.48	-0.59	0.42	0.76	0.57		0.67	0.82	0.57	0.76	0.75	0.98	0.08	0.8	0.24	0.88	0.69	0.7	0.05
Common Stock Total Equity	-0.17	0.77	0.82	0.68	0.77	0.38	0.32	-0.07	-0.96	0.5	0.47	0.86	0.67		0.6	0.61	0.91	0.83	0.75	0.74	0.34	0.0	0.72	0.72	0.74	0.73
Non Current Liabilities Total	0.08	0.82	0.89	0.6	0.51	0.65	0.61	-0.13	-0.64	0.32	0.51	0.59	0.82	0.6		0.42	0.77	0.81	0.8	0.11	0.58	-0.24	0.6	0.76	0.78	0.08
Other Current Assets	-0.27	0.66	0.46	0.94	0.9	0.35	0.8	-0.5	-0.52	0.93	0.68	0.71	0.57	0.61	0.42		0.56	0.8	0.62	0.24	0.58	0.17	0.43	0.88	0.86	0.3
Other Stockholder Equity	0.03	0.8	0.95	0.67	0.76	0.49	0.37	-0.01	-0.94	0.4	0.44	0.84	0.76	0.91	0.77	0.56		0.88	0.78	0.58	0.39	-0.07	0.75	0.76	0.79	0.54
Total Liab	-0.07	0.82	0.88	0.93	0.92	0.44	0.74	-0.24	-0.82	0.72	0.63	0.88	0.75	0.83	0.81	0.8	0.88		0.78	0.42	0.56	-0.1	0.59	0.95	0.97	0.45
Total Current Assets	-0.18	1.0	0.75	0.67	0.6	0.86	0.55	-0.45	-0.67	0.48	0.77	0.65	0.98	0.75	0.8	0.62	0.78	0.78		0.21	0.76	0.21	0.89	0.73	0.75	0.19
Short Term Debt	0.09	0.23	0.5	0.29	0.48	-0.2	-0.12	0.37	-0.8	0.12	-0.06	0.61	0.08	0.74	0.11	0.24	0.58	0.42	0.21		-0.21	-0.22	0.38	0.3	0.33	0.97
Common Stock	-0.3	0.76	0.41	0.59	0.46	0.79	0.72	-0.56	-0.2	0.48	0.69	0.33	0.8	0.34	0.58	0.58	0.39	0.56	0.76	-0.21		0.22	0.59	0.58	0.57	-0.24
Other Liab	-0.31	0.18	-0.31	0.04	0.03	0.39	-0.15	-0.64	0.16	0.25	0.46	0.07	0.24	0.0	-0.24	0.17	-0.07	-0.1	0.21	-0.22	0.22		0.29	-0.12	-0.14	-0.18
Net Tangible Assets	-0.07	0.87	0.67	0.43	0.45	0.81	0.22	-0.34	-0.65	0.19	0.62	0.51	0.88	0.72	0.6	0.43	0.75	0.59	0.89	0.38	0.59	0.29		0.47	0.5	0.31
Property Plant And Equipment Net	-0.1	0.78	0.77	0.95	0.88	0.41	0.84	-0.24	-0.72	0.8	0.58	0.83	0.69	0.72	0.76	0.88	0.76	0.95	0.73	0.3	0.58	-0.12	0.47		1.0	0.32
Non Current Assets Total	-0.08	0.79	0.8	0.94	0.89	0.41	0.82	-0.23	-0.75	0.78	0.58	0.84	0.7	0.74	0.78	0.86	0.79	0.97	0.75	0.33	0.57	-0.14	0.5	1.0		0.35
Non Currrent Assets Other	0.03	0.21	0.46	0.36	0.54	-0.26	-0.05	0.23	-0.76	0.22	0.05	0.61	0.05	0.73	0.08	0.3	0.54	0.45	0.19	0.97	-0.24	-0.18	0.31	0.32	0.35

Click cells to compare fundamentals

Corbus Pharmaceuticals Account Relationship Matchups

Corbus Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Common Stock Shares Outstanding	2.1M	2.6M	4.1M	4.2M	4.3M	2.9M
Total Assets	49.1M	102.3M	107.7M	66.3M	28.3M	50.5M
Short Long Term Debt Total	9.4M	26.8M	26.6M	25.1M	20.9M	11.1M
Other Current Liab	22.4M	21.8M	10.2M	6.0M	11.1M	9.0M
Total Current Liabilities	34.9M	31.9M	17.0M	12.6M	31.9M	16.9M
Total Stockholder Equity	6.2M	45.3M	69.1M	33.0M	(6.9M)	(6.6M)
Net Debt	(22.3M)	(58.6M)	1.6M	8.1M	7.0M	7.3M
Retained Earnings	(192.8M)	(304.1M)	(349.7M)	(392.1M)	(436.7M)	(414.8M)
Accounts Payable	11.1M	7.4M	1.8M	2.2M	3.2M	4.0M
Cash	31.7M	85.4M	25.0M	17.0M	13.9M	13.2M
Cash And Short Term Investments	31.7M	85.4M	97.6M	59.2M	20.9M	19.9M
Common Stock Total Equity	5.6K	5.7K	6.5K	9.9K	11.4K	11.9K
Liabilities And Stockholders Equity	49.1M	102.3M	107.7M	66.3M	28.3M	50.5M
Non Current Liabilities Total	8.1M	25.1M	21.6M	20.7M	3.3M	3.1M
Other Current Assets	6.4M	4.1M	2.6M	984.1K	2.6M	2.4M
Other Stockholder Equity	199.0M	349.4M	418.9M	425.2M	429.8M	216.4M
Total Liab	43.0M	57.0M	38.6M	33.3M	35.2M	25.1M
Total Current Assets	38.2M	92.1M	100.2M	60.2M	23.5M	46.1M
Short Term Debt	1.3M	2.7M	5.0M	4.4M	17.6M	18.5M
Common Stock	6.5K	9.9K	12.5K	417.0	442.0	419.9
Net Tangible Assets	6.2M	45.3M	69.1M	33.0M	37.9M	32.1M
Property Plant And Equipment Net	10.9M	9.3M	7.0M	5.5M	4.0M	4.6M
Non Current Assets Total	11.0M	10.2M	7.5M	6.1M	4.7M	4.9M
Non Currrent Assets Other	85.0K	234.0K	46.4K	155.3K	690.2K	724.7K
Retained Earnings Total Equity	(65.7M)	(121.4M)	(192.8M)	(304.1M)	(273.7M)	(260.0M)
Capital Surpluse	123.5M	148.9M	199.0M	349.4M	401.8M	421.9M
Property Plant And Equipment Gross	10.9M	9.3M	7.0M	5.5M	7.6M	5.0M
Short Long Term Debt	752.7K	710.2K	3.9M	3.1M	16.2M	17.0M
Accumulated Other Comprehensive Income	(666.6K)	(1.4M)	(62.4K)	(126.1K)	(1.6K)	(1.6K)
Property Plant Equipment	5.1M	9.3M	7.0M	5.5M	6.3M	3.9M

Pair Trading with Corbus Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Corbus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Corbus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Corbus Stock

0.84

VALN

Valneva SE ADR Downward Rally

Pair Corr

Moving against Corbus Stock

0.69	KZR	Kezar Life Sciences	Pair Corr
0.61	MLYS	Mineralys Therapeutics, Downward Rally	Pair Corr

The ability to find closely correlated positions to Corbus Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Corbus Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Corbus Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Corbus Pharmaceuticals Holding to buy it.

The correlation of Corbus Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Corbus Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Corbus Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Corbus Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Corbus Stock Analysis

When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC